Tyrosinase-derived peptide-Major Histocompatibility Complex (TYR-pMHC)

Tyrosinase-derived peptide epitopes presented by the Major Histocompatibility Complex (MHC) are primary targets for melanoma immunotherapy (PubMed: 8146140). Tyrosinase is a rate-limiting enzyme in melanin production, and its expression is highly specific to melanocytes and their malignant counterpart, melanoma (UniProt: P14679). In the context of the immune system, tyrosinase is processed into short peptides that are presented on the cell surface by MHC molecules, particularly HLA-A*02:01 (PubMed: 7524369). Dendritic cells (DCs) are often utilized in clinical settings to present these epitopes to T cells, effectively priming the immune system to recognize and destroy melanoma cells (PubMed: 11313912). Therapeutic interventions include peptide vaccines, DC-based vaccines, and adoptive cell transfers using T cells engineered with T-cell receptors (TCRs) specific for the tyrosinase-MHC complex (PubMed: 15343348). While effective in inducing anti-tumor responses, targeting these epitopes can lead to vitiligo, an autoimmune condition characterized by the loss of skin pigment due to the destruction of healthy melanocytes (PubMed: 10491014). Monitoring for HLA-A*02:01 expression is frequently required for patient selection, as many tyrosinase epitopes are restricted to this specific MHC allele. This target represents a cornerstone of personalized cancer vaccines and cellular therapies aimed at leveraging the specificity of the adaptive immune system against solid tumors.

Other names

Tyrosinase-derived epitopesHLA-restricted tyrosinase antigenMelanoma-associated antigen tyrosinaseTyrosinase peptide-HLA-A*02:01 complexTyrosinase-derived peptide-MHC complex

Induction of antigen-specific cytotoxic T-lymphocyte (CTL) responses through the presentation of tyrosinase-derived peptides by MHC molecules to T-cell receptors (PubMed: 8146140).